DK2502996T3 - Anti-FGF23-antistof og farmaceutisk sammensætning omfattende samme - Google Patents
Anti-FGF23-antistof og farmaceutisk sammensætning omfattende samme Download PDFInfo
- Publication number
- DK2502996T3 DK2502996T3 DK12170984.4T DK12170984T DK2502996T3 DK 2502996 T3 DK2502996 T3 DK 2502996T3 DK 12170984 T DK12170984 T DK 12170984T DK 2502996 T3 DK2502996 T3 DK 2502996T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody
- fgf23
- seq
- amino acid
- nucleotide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Neurology (AREA)
Claims (13)
1. Antistof mod human FGF23 eller et funktionelt fragment af antistoffet mod human FGF23, a) hvor antistoffet mod human FGF23 eller det funktionelle fragment af antistoffet omfatter en tung kæde variabel region med komplementaritetsbestemmende region (CDR) l vist med aminosyresekvensen af SEQ ID NO:40, CDR2 vist med aminosyresekvensen af SEQ ID N0:41 og CDR3 vist med aminosyresekvensen af SEQ ID NO:42, og en let kæde variabel region med komplementaritetsbestemmende region (CDR) 1 vist med aminosyresekvensen af SEQ ID NO:43, CDR2 vist med aminosyresekvensen af SEQ ID NO:44 og CDR3 vist med aminosyresekvensen af SEQ ID NO:45, eller b) hvor antistoffet mod human FGF23 er frembragt ved hybridom FERM BP- 10772, eller c) hvilket antistof eller fragment omfatter den samme aminosyresekvens som en tung kæde variabel region og en let kæde variabel region af et antistof frembragt ved hybridom FERM BP-10772.
2. Det funktionelle fragment ifølge krav 1, hvor det funktionelle fragment er et peptidfragment valgt fra gruppen bestående af Fab, Fab', F (ab')2, disulfid-stabiliseret Fv (dsFv), dimeriseret V region (diabody), enkeltkæde Fv (scFv) og CDR.
3. Antistoffet mod human FGF23 eller funktionelt fragment af antistoffet ifølge krav 1 eller 2, omfattende en tung kæde eller let kæde med en aminosyresekvens i hvilken en eller flere aminosyrer er deleteret, substitueret eller tilføjet.
4. Antistoffet mod human FGF23 ifølge et hvilket som helst af de foregående krav, hvor klassen af antistoffet er valgt fra gruppen bestående af IgG, IgA, IgE, og IgM.
5. Antistoffet mod human FGF23 ifølge et hvilket som helst af de foregående krav, hvor underklassen af IgG-antistoffet er valgt fra gruppen bestående af IgGl, IgG2, IgG3, og IgG4.
6. Farmaceutisk sammensætning, omfattende som en aktiv bestanddel antistoffet mod human FGF23 eller funktionelt fragment af antistoffet ifølge et hvilket som helst af kravene 1-5.
7. Farmaceutisk sammensætning til anvendelse i en fremgangsmåde til at forebygge eller behandle en sygdom, der er associeret med mineralstofskiftesygdomme, hvilken sammensætning omfatter som en aktiv bestanddel antistoffet mod human FGF23 eller funktionelt fragment af antistoffet ifølge et hvilket som helst af kravene 1-5, hvor sygdommen, der er associeret med mineralstofskiftesygdomme er valgt fra gruppen bestående af neoplastisk osteomalaci, ADHR, XLH, fibrøs dysplasi, McCune-Albright-syndrom, og autosomal recessiv hypofosfatæmi.
8. Farmaceutisk sammensætning til anvendelse i en fremgangsmåde til at forebygge eller behandle en sygdom valgt fra gruppen bestående af osteoporose, rakitis, hypercalcæmi, hypocalcæmi, heterotrop forkalkning, osteosklerose, Pagets sygdom, hyperparathyreoidisme, hypoparathyreoidisme, og pruritus, hvilken sammensætning omfatter som en aktiv bestanddel antistoffet mod human FGF23 eller funktionelt fragment af antistoffet ifølge et hvilket som helst af kravene 1-5.
9. Hybridom deponeret med accessionsnummer FERM BP-10772.
10. Nukleinsyre der koder for en tung kæde variabel region og en let kæde variabel region omfattende sekvensen fra nukleotidet i position 58 af SEQ ID NO: 11 til nukleotidet i position 408 af SEQ ID NO: 11 og sekvensen fra nukleotidet i position 67 af SEQ ID NO: 13 til nukleotidet i position 384 af SEQ ID NO: 13.
11. Vektor omfattende nukleinsyren ifølge krav 10.
12. Værtscelle omfattende vektoren ifølge krav 11.
13. Fremgangsmåde til fremstilling af et antistof mod human FGF23 eller et funktionelt fragment af antistoffet, omfattende trinnet at dyrke en værtscelle, a) hvilken værtscelle omfatter en nukleinsyre, der koder for en aminosyresekvens afen tung kæde variabel region kodet af nukleotidsekvensen fra nukleotidet i position 58 af SEQ ID NO:ll til nukleotidet i position 408 af SEQ ID NO: 11 og der koder for en aminosyresekvens afen let kæde variabel region kodet af nukleotidsekvensen fra nukleotidet i position 67 af SEQ ID NO: 13 til nukleotidet i position 384 af SEQ ID NO: 13, eller b) hvilken værtscelle omfatter nukleinsyren ifølge krav 10, eller c) hvilken værtscelle omfatter en vektor omfattende en nukleinsyre der koder for en aminosyresekvens af en tung kæde variabel region kodet af nukleotidsekvensen fra nukleotidet i position 58 af SEQ ID NO:ll til nukleotidet i position 408 af SEQ ID NO: 11 og en vektor omfattende en nukleinsyre der koder for en aminosyresekvens afen let kæde variabel region kodet af nukleotidsekvensen fra nukleotidet i position 67 af SEQ ID NO: 13 til nukleotidet i position 384 af SEQ ID NO: 13, eller d) hvilken værtscelle omfatter en vektor omfattende en nukleinsyre der koder for en aminosyresekvens af en tung kæde variabel region og en let kæde variabel region kodet af nukleotidsekvensen fra nukleotidet i position 58 af SEQ ID NO: 11 til nukleotidet iposition 408 af SEQ ID NO: 11 og nukleotidsekvensen fra nukleotidet i position 67 af SEQ ID NO: 13 til nukleotidet i position 384 af SEQ ID NO: 13, henholdsvis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007034018 | 2007-02-14 | ||
| EP08711707.3A EP2128253B1 (en) | 2007-02-14 | 2008-02-14 | Anti-fgf23 antibody and pharmaceutical composition comprising the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2502996T3 true DK2502996T3 (da) | 2017-05-08 |
Family
ID=39690189
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12170984.4T DK2502996T3 (da) | 2007-02-14 | 2008-02-14 | Anti-FGF23-antistof og farmaceutisk sammensætning omfattende samme |
| DK08711707.3T DK2128253T3 (da) | 2007-02-14 | 2008-02-14 | Anti-fgf23-antistof og farmaceutisk sammensætning omfattende samme |
| DK17152168.5T DK3181691T3 (da) | 2007-02-14 | 2008-02-14 | Anti-fgf23-antistof og en farmaceutisk sammensætning omfattende samme |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08711707.3T DK2128253T3 (da) | 2007-02-14 | 2008-02-14 | Anti-fgf23-antistof og farmaceutisk sammensætning omfattende samme |
| DK17152168.5T DK3181691T3 (da) | 2007-02-14 | 2008-02-14 | Anti-fgf23-antistof og en farmaceutisk sammensætning omfattende samme |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US7883705B2 (da) |
| EP (3) | EP2502996B1 (da) |
| JP (1) | JP4800396B2 (da) |
| KR (1) | KR101462291B1 (da) |
| CN (2) | CN102702355B (da) |
| AU (1) | AU2008215346B2 (da) |
| CA (1) | CA2677782C (da) |
| CY (3) | CY1118835T1 (da) |
| DK (3) | DK2502996T3 (da) |
| ES (3) | ES2811318T3 (da) |
| FR (1) | FR18C1032I2 (da) |
| HR (2) | HRP20170548T1 (da) |
| HU (3) | HUE050517T2 (da) |
| LT (3) | LT2502996T (da) |
| LU (2) | LUC00081I2 (da) |
| NL (1) | NL300945I2 (da) |
| NO (1) | NO2018025I1 (da) |
| PL (3) | PL2128253T3 (da) |
| PT (3) | PT3181691T (da) |
| SI (2) | SI2502996T1 (da) |
| TW (1) | TWI422593B (da) |
| WO (1) | WO2008099969A1 (da) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2233571B1 (en) * | 2000-08-11 | 2012-11-07 | Kyowa Hakko Kirin Co., Ltd. | Polypeptide regulating phosphate metabolism, calcium metabolism, calcification and vitamin D metabolism and DNAS encoding the same |
| JP4527982B2 (ja) * | 2001-12-28 | 2010-08-18 | 協和発酵キリン株式会社 | 線維芽細胞増殖因子−２３に対する抗体 |
| US7883705B2 (en) | 2007-02-14 | 2011-02-08 | Kyowa Hakko Kirin Co., Ltd. | Anti FGF23 antibody and a pharmaceutical composition comprising the same |
| WO2012050673A1 (en) * | 2010-10-14 | 2012-04-19 | Wisconsin Alumni Research Foundation | Methods for the treatment of x-linked hypophosphatemia and related disorders |
| US20140294820A1 (en) | 2011-06-24 | 2014-10-02 | University Of Miami | Fibroblast growth factor receptor inhibition for the treatment of disease |
| MX381052B (es) | 2014-06-09 | 2025-03-12 | Ultragenyx Pharmaceutical Inc | El control efectivo y eficaz del fosfato serico para una osificacion optima. |
| WO2018069232A1 (en) | 2016-10-10 | 2018-04-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the risk of having cardiac hypertrophy |
| WO2018181935A1 (ja) | 2017-03-30 | 2018-10-04 | シスメックス株式会社 | 抗ＡｐｏＡ１抗体 |
| BR112021019337A2 (pt) * | 2019-03-29 | 2021-12-07 | Atarga Llc | Anticorpo anti-fgf23 |
| KR20250049545A (ko) | 2022-08-10 | 2025-04-11 | 쿄와 기린 가부시키가이샤 | 항fgf23 항체 또는 해당 항체 단편 |
| EP4676955A2 (en) * | 2023-03-10 | 2026-01-14 | Ultragenyx Pharmaceutical Inc. | Human fgf23-binding antibodies with improved affinity and efficacy |
| CN119080938B (zh) * | 2023-06-05 | 2025-06-24 | 东莞市朋志生物科技有限公司 | 抗25羟维生素d抗体、检测25羟维生素d的试剂和试剂盒 |
| JP7826558B1 (ja) | 2024-10-11 | 2026-03-09 | ノヴォ ノルディスク アー／エス | ヒトｆｇｆ２３のアンタゴニスト |
| CN119954951A (zh) * | 2024-12-31 | 2025-05-09 | 上海良润生物医药科技有限公司 | iFGF23特异性抗体及其在制备慢性肾病辅助诊断试剂中的应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5623587A (en) | 1979-08-03 | 1981-03-05 | Mitsuwa Seiki Co Ltd | Vane type compressor |
| WO1985003934A1 (fr) | 1984-03-06 | 1985-09-12 | Takeda Chemical Industries, Ltd. | Proteine modifiee chimiquement et son procede de preparation |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61178926U (da) | 1985-04-23 | 1986-11-08 | ||
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| FI884924L (fi) | 1987-10-28 | 1989-04-29 | Oncogen | Humanimmuglobulin som producerats med hybrid-dna-teknik. |
| JP2958019B2 (ja) | 1988-05-06 | 1999-10-06 | 住友製薬株式会社 | ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5958879A (en) * | 1989-10-12 | 1999-09-28 | Ohio University/Edison Biotechnology Institute | Growth hormone receptor antagonists and methods of reducing growth hormone activity in a mammal |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| CN100359015C (zh) | 1998-05-18 | 2008-01-02 | 伦敦大学专科学院 | 多肽激素磷酸盐沉着因子 |
| TWI255853B (en) | 1998-08-21 | 2006-06-01 | Kirin Brewery | Method for modifying chromosomes |
| AU3924300A (en) | 1999-04-02 | 2000-10-23 | Millennium Pharmaceuticals, Inc. | Fibroblast growth factor-20 |
| US6596849B1 (en) * | 1999-05-28 | 2003-07-22 | Academia Sinica | Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules |
| JP2004522402A (ja) | 1999-06-02 | 2004-07-29 | ジェネンテック・インコーポレーテッド | 同一のものをコードする分泌及び膜貫通ポリペプチドと核酸 |
| CA2491433A1 (en) | 1999-12-01 | 2001-06-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| JP2003516150A (ja) | 1999-12-08 | 2003-05-13 | ジェンセット | 潜在性分泌タンパク質をコードする全長ヒトｃＤＮＡ |
| EP1246843A1 (en) | 2000-01-05 | 2002-10-09 | ZymoGenetics, Inc. | Novel fgf homolog zfgf12 |
| AU2001239765A1 (en) | 2000-02-14 | 2001-08-27 | Smith Kline Beecham Corporation | Novel compounds |
| AU3976701A (en) | 2000-02-15 | 2001-08-27 | Amgen, Inc. | Fibroblast growth factor-23 molecules and uses thereof |
| US20060160181A1 (en) * | 2000-02-15 | 2006-07-20 | Amgen Inc. | Fibroblast Growth Factor-23 molecules and uses thereof |
| WO2001066595A2 (en) | 2000-03-08 | 2001-09-13 | Chiron Corporation | Human fgf-23 gene and gene expression products |
| AU2001245535A1 (en) | 2000-03-08 | 2001-09-17 | Chiron Corporation | Human fgf-23 gene and gene expression products |
| ATE461213T1 (de) | 2000-07-19 | 2010-04-15 | Advanced Res & Tech Inst | Neuer fibroblastwachstumsfaktor (fgf23) und methoden zur verwendung |
| EP2233571B1 (en) * | 2000-08-11 | 2012-11-07 | Kyowa Hakko Kirin Co., Ltd. | Polypeptide regulating phosphate metabolism, calcium metabolism, calcification and vitamin D metabolism and DNAS encoding the same |
| CA2430013C (en) | 2000-11-30 | 2011-11-22 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
| WO2002076467A1 (en) | 2001-03-22 | 2002-10-03 | Genzyme Corporation | Compositions and methods to regulate bone and mineral metabolism |
| US20040171825A1 (en) * | 2001-04-26 | 2004-09-02 | Lydie Bougueleret | Human fibroblast growth factor-related compositions |
| CA2658221C (en) * | 2001-04-27 | 2012-11-27 | Kyowa Kirin Co., Ltd. | Anti-cd40 monoclonal antibody |
| JP4527982B2 (ja) | 2001-12-28 | 2010-08-18 | 協和発酵キリン株式会社 | 線維芽細胞増殖因子−２３に対する抗体 |
| US7094551B2 (en) * | 2002-09-17 | 2006-08-22 | Zahradnik Richard J | Immunoassays, assay methods, antibodies and method of creating antibodies for detecting FGF-23 |
| WO2004083425A1 (ja) * | 2003-03-17 | 2004-09-30 | Kirin Beer Kabushiki Kaisha | 歯周病治療剤 |
| CA2569509C (en) * | 2004-06-03 | 2014-08-12 | Novimmune S.A. | Anti-cd3 antibodies and methods of use thereof |
| CA2575402A1 (en) * | 2004-08-05 | 2006-02-09 | Genentech, Inc. | Humanized anti-cmet antagonists |
| WO2006028197A1 (ja) * | 2004-09-06 | 2006-03-16 | Kirin Beer Kabushiki Kaisha | 抗a33抗体 |
| JPWO2006078072A1 (ja) | 2005-01-21 | 2008-06-19 | キリンファーマ株式会社 | キメラ非ヒト動物およびその使用 |
| EP2054521A4 (en) | 2006-10-03 | 2012-12-19 | Novo Nordisk As | PROCESS FOR CLEANING POLYPEPTIDE CONJUGATES |
| US20100062984A1 (en) * | 2007-01-25 | 2010-03-11 | Rajiv Kumar | Fgf-23 polypeptides |
| US7883705B2 (en) * | 2007-02-14 | 2011-02-08 | Kyowa Hakko Kirin Co., Ltd. | Anti FGF23 antibody and a pharmaceutical composition comprising the same |
-
2008
- 2008-02-13 US US12/030,593 patent/US7883705B2/en active Active
- 2008-02-14 PT PT171521685T patent/PT3181691T/pt unknown
- 2008-02-14 LU LU00081C patent/LUC00081I2/en unknown
- 2008-02-14 CN CN201210161119.8A patent/CN102702355B/zh active Active
- 2008-02-14 ES ES17152168T patent/ES2811318T3/es active Active
- 2008-02-14 PL PL08711707T patent/PL2128253T3/pl unknown
- 2008-02-14 JP JP2008558165A patent/JP4800396B2/ja active Active
- 2008-02-14 SI SI200831797T patent/SI2502996T1/sl unknown
- 2008-02-14 EP EP12170984.4A patent/EP2502996B1/en active Active
- 2008-02-14 LU LU00082C patent/LUC00082I2/en unknown
- 2008-02-14 HU HUE17152168A patent/HUE050517T2/hu unknown
- 2008-02-14 DK DK12170984.4T patent/DK2502996T3/da active
- 2008-02-14 ES ES12170984T patent/ES2625823T3/es active Active
- 2008-02-14 PT PT121709844T patent/PT2502996T/pt unknown
- 2008-02-14 CN CN2008800048145A patent/CN101652476B/zh active Active
- 2008-02-14 CA CA2677782A patent/CA2677782C/en active Active
- 2008-02-14 PT PT87117073T patent/PT2128253E/pt unknown
- 2008-02-14 DK DK08711707.3T patent/DK2128253T3/da active
- 2008-02-14 AU AU2008215346A patent/AU2008215346B2/en active Active
- 2008-02-14 HU HUE12170984A patent/HUE031728T2/en unknown
- 2008-02-14 KR KR1020097019085A patent/KR101462291B1/ko active Active
- 2008-02-14 PL PL17152168T patent/PL3181691T3/pl unknown
- 2008-02-14 PL PL12170984T patent/PL2502996T3/pl unknown
- 2008-02-14 TW TW097105234A patent/TWI422593B/zh active
- 2008-02-14 EP EP17152168.5A patent/EP3181691B1/en active Active
- 2008-02-14 LT LTEP12170984.4T patent/LT2502996T/lt unknown
- 2008-02-14 ES ES08711707T patent/ES2530670T3/es active Active
- 2008-02-14 WO PCT/JP2008/052918 patent/WO2008099969A1/ja not_active Ceased
- 2008-02-14 LT LTEP17152168.5T patent/LT3181691T/lt unknown
- 2008-02-14 SI SI200832131T patent/SI3181691T1/sl unknown
- 2008-02-14 EP EP08711707.3A patent/EP2128253B1/en active Active
- 2008-02-14 DK DK17152168.5T patent/DK3181691T3/da active
-
2011
- 2011-02-02 US US13/019,557 patent/US9290569B2/en active Active
-
2016
- 2016-02-10 US US15/040,103 patent/US10202446B2/en active Active
-
2017
- 2017-04-04 HR HRP20170548TT patent/HRP20170548T1/hr unknown
- 2017-04-19 CY CY20171100446T patent/CY1118835T1/el unknown
-
2018
- 2018-07-27 NL NL300945C patent/NL300945I2/en unknown
- 2018-07-27 FR FR18C1032C patent/FR18C1032I2/fr active Active
- 2018-08-01 LT LTPA2018508C patent/LTC2502996I2/lt unknown
- 2018-08-02 HU HUS1800034C patent/HUS1800034I1/hu unknown
- 2018-08-07 CY CY2018021C patent/CY2018021I2/el unknown
- 2018-08-09 NO NO2018025C patent/NO2018025I1/no unknown
- 2018-12-18 US US16/223,930 patent/US20190106485A1/en not_active Abandoned
-
2020
- 2020-08-03 CY CY20201100713T patent/CY1123240T1/el unknown
- 2020-08-11 HR HRP20201266TT patent/HRP20201266T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2502996T3 (da) | Anti-FGF23-antistof og farmaceutisk sammensætning omfattende samme | |
| CN107722122B (zh) | Vegf/dll4结合剂及其应用 | |
| CN101679521B (zh) | 特异性结合cd154的包括抗体、抗体衍生物和抗体片段在内的结合蛋白及其用途 | |
| US9115195B2 (en) | Therapeutic DLL4 binding proteins | |
| KR20100099193A (ko) | Ｗｉｓｅ 결합 항체 및 에피토프 | |
| KR20120102623A (ko) | 조작된 항－ｔｓｌｐ 항체 | |
| EP3029070A1 (en) | Therapeutic dll4 binding proteins | |
| KR102880176B1 (ko) | Apj 항체 및 이와 엘라벨라의 융합 단백질, 및 그의 약학 조성물 및 적용 | |
| HK1140228B (en) | Anti fgf23 antibody and pharmaceutical composition comprising the same | |
| WO2025253118A2 (en) | Tlr4 antibody | |
| HK1172917B (en) | Anti fgf23 antibody and a pharmaceutical composition comprising the same | |
| HK1249121B (en) | Vegf/dll4 binding agents and uses thereof | |
| HK1249121A1 (en) | Vegf/dll4 binding agents and uses thereof |